Search
for
Sort by
Research 781–810 of 1000+
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Efficacy of Fire Needle Therapy Combined with Doxycycline Hydrochloride in the Management of Moderate-to-Severe Acne Vulgaris: A Randomized Controlled Trial
- Atypical presentation of Acrodermatitis enteropathica in a child: later onset with life-threatening severe extensive dermatitis and septic shock
- RETRACTION: Observing the Clinical Efficacy of Combined Serum Microneedle Therapy for Moderate to Severe Androgenetic Alopecia in Scalp Repair
- Response to Li et al.’s “Therapeutic efficacy of platelet-rich plasma combining with microneedling and topical minoxidil in refractory severe androgenic alopecia”
- Trichoscopic evaluation in oral tofacitinib and oral betamethasone in the treatment of moderate to severe alopecia areata
- Therapeutic Efficacy of Platelet-Rich Plasma Combining with Microneedling and Topical Minoxidil in Refractory Severe Androgenic Alopecia
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- Observing the clinical efficacy of combined serum microneedle therapy for moderate to severe androgenetic alopecia in scalp repair
- Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata
- 42146 Concurrent improvement in scalp hair and eyebrow or eyelash regrowth in patients with severe alopecia areata treated with baricitinib
- 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
- Finasteride Induces Epigenetic Alteration of TMPRss2 Gene Expression: A Potential role in Severe Acute Respiratory Syndrome-Corona Virus-2 Inhibition
- 738 Cryo-EM and molecular dynamics of TRPV3 channel in activated state reveal structural features implicated in severe itch and hyperkeratosis
- Identification of a novel homozygous LAMB3 mutation in a Chinese male with junctional epidermolysis bullosa and severe urethra stenosis: A case report
- Re-discovery of Trichophyton bullosum in North Africa as a cause of severe dermatophytosis in donkeys
- Evaluation of Efficacy and Safety of Oral Cyclosporine in the Treatment of Severe Alopecia Areata
- Compound Heterozygous Mutations in <i>Forkhead Box N1</i> (<i>FOXN1</i>) Lead to a Severe Immunodeficiency but Normal Hair and Nail Development in Patients
- PS10:189 Neuropsychiatric lupus. a severe manifestation of systemic lupus erythematosus
- Implanted hair follicle stem cells form Schwann cells that support repair of severed peripheral nerves
- Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children
- Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia
- Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice
- Epidermal dysplasia and <i>Malassezia</i> infection in two West Highland White Terrier siblings: an inherited skin disorder or reaction to severe <i>Malassezia</i> infection?
- Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata
- The relationship among androgens, insulin resistanceand ghrelin polymorphisms in post-adolescent malepatients with severe acne vulgaris
- Maintenance effect of a once-weekly regimen of a Selenium Disulfide-based shampoo in moderate-to-severe scalp seborrheic dermatitis after initial treatment with topical corticosteroid/salicylic acid
- P63 targeted deletion under the FOXN1 promoter disrupts pre-and post-natal thymus development, function and maintenance as well as induces severe hair loss
- Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata